Immunocore Holdings (IMCR) Change in Accured Expenses (2023 - 2026)

Immunocore Holdings has disclosed Change in Accured Expenses across 4 years of filings, most recently posting -$8.3 million for Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$8.3 million, up 24.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.6 million (up 121.75% YoY), and the FY2023 annual result was $39.1 million, up 1728.25% from the prior year.
• Change in Accured Expenses came in at -$8.3 million for Q1 2026 at Immunocore Holdings, up from -$37.9 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $44.8 million in Q2 2024 to a low of -$72.7 million in Q4 2024.
• The 4-year median for Change in Accured Expenses is $10.9 million (2025), against an average of $2.4 million.
• Across the five-year window, Change in Accured Expenses soared 363.36% in 2024 and slumped 1017.27% in 2025, its largest moves.
• Immunocore Holdings' Change in Accured Expenses stood at $16.0 million in 2023, then slumped by 555.15% to -$72.7 million in 2024, then jumped by 47.86% to -$37.9 million in 2025, then surged by 78.1% to -$8.3 million in 2026.
• The last three Change in Accured Expenses figures came in at -$8.3 million (Q1 2026), -$37.9 million (Q4 2025), and $37.9 million (Q3 2025), per Business Quant data.